drugset

drugset / Trial / NCT00136994

IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)

NCT00136994 ↗

Phase 3 Completed 160 enrolled Viatris Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia

Timeline

Start: 2003-03
Primary completion: —
Completion: 2005-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ziprasidone	Small molecule	—	Intramuscular

Indications